1.
Global, regional, and national disability-adjusted life-years (DALYs) for 333 diseases and injuries and healthy life expectancy (HALE) for 195 countries and territories, 1990–2016:...
by Abate, Kalkidan Hassen
The Lancet (British edition), 2017-09-16, Vol.390 (10100), p.1260-1344
2.
Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks, 1990–2016: a systematic anal...
by Gakidou, Emmanuela
The Lancet (British edition), 2017-09-16, Vol.390 (10100), p.1345-1422
3.
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Glob...
by Abd-Allah, Foad
The Lancet (British edition), 2017-09-16, Vol.390 (10100), p.1211-1259
4.
Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease St...
by Abate, Kalkidan Hassen
The Lancet (British edition), 2017-09-16, Vol.390 (10100), p.1084-1150
5.
Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of...
by Abate, Kalkidan Hassen
The Lancet (British edition), 2017-09-16, Vol.390 (10100), p.1423-1459
6.
Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies
by Sarwar, N
The Lancet (British edition), 2010, Vol.375 (9733), p.2215-2222
7.
Global, regional, and national levels and causes of maternal mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
by Bertozzi-Villa, Amelia, BA
The Lancet (British edition), 2014, Vol.384 (9947), p.980-1004
8.
Global, regional, and national under-5 mortality, adult mortality, age-specific mortality, and life expectancy, 1970–2016: a systematic analysis for the Global Burden of Disease St...
by Abate, Kalkidan Hassen
The Lancet (British edition), 2017-09-16, Vol.390 (10100), p.1084-1150
9.
Glycemia but not the Metabolic Syndrome is Associated with Cognitive Decline: Findings from the European Male Ageing Study
by Overman, Margot J., M.Sc
The American journal of geriatric psychiatry, 2017, Vol.25 (6), p.662-671
10.
Attributes and predictors of long COVID
by Sudre, Carole H
Nature Medicine, 2021-04, Vol.27 (4), p.626-631
11.
Job strain as a risk factor for coronary heart disease: a collaborative meta-analysis of individual participant data
by Kivimäki, Mika, Prof
The Lancet (British edition), 2012, Vol.380 (9852), p.1491-1497
12.
Smoking prevalence and attributable disease burden in 195 countries and territories, 1990–2015: a systematic analysis from the Global Burden of Disease Study 2015
by Reitsma, Marissa B
The Lancet (British edition), 2017, Vol.389 (10082), p.1885-1906
13.
Midlife Fruit and Vegetable Consumption and Risk of Dementia in Later Life in Swedish Twins
by Hughes, Tiffany F., Ph.D., M.P.H
The American journal of geriatric psychiatry, 2010, Vol.18 (5), p.413-420
14.
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes
by Mavaddat, Nasim Nasim
American journal of human genetics, 2018-12-13, Vol.104 (1), p.21-34
15.
Mortality after surgery in Europe: a 7 day cohort study
by Pearse, Rupert M, Dr
The Lancet (British edition), 2012, Vol.380 (9847), p.1059-1065
16.
The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study
by Hijazi, Ziad, Dr
The Lancet (British edition), 2016, Vol.387 (10035), p.2302-2311
17.
Genome-wide Analyses Identify KIF5A as a Novel ALS Gene
by Kenna, Kevin P
Neuron (Cambridge, Mass.), 2018-03-21, Vol.97 (6), p.1268-1283.e6
18.
Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled...
by Azzouzi, Abdel-Rahmène, Prof
The lancet oncology, 2016, Vol.18 (2), p.181-191
19.
Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial
by Saussele, Susanne
The lancet oncology, 2018-06, Vol.19 (6), p.747-757
20.
Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial
by Giugliano, Robert P
The Lancet (British edition), 2017-10-28, Vol.390 (10106), p.1962-1971
Filter electronic articles 14.049 Hits
Remove Filters
